Laserfiche WebLink
<br />3 <br /> <br /> <br />resolved prior to that date. A list of all Litigating Subdivisions known to the Parties <br />is included in Exhibit F hereto. <br />13. “Net Settlement Amount” means the amount paid by Janssen into the Settlement <br />Fund under subsection V.C. For the avoidance of doubt, the Net Settlement Amount <br />does not include amounts paid for State Outside and Inside Counsel Fees and Costs <br />pursuant to subsection IX.A. <br />14. “Non-Litigating Subdivision” means a Subdivision that is not a Litigating <br />Subdivision. <br />15. “Non-Party Covered Conduct Claim” means a Claim against any Non-Released <br />Entity involving, arising out of, or related to Covered Conduct (or conduct that <br />would be Covered Conduct if engaged in by a Released Entity). <br />16. “Non-Party Settlement” means a settlement by any Releasor that settles any Non- <br />Party Covered Conduct Claim and includes a release of any Non-Released Entity. <br />17. “Non-Released Entity” means an entity that is not a Released Entity. <br />18. “Opioid Remediation” means care, treatment, and other programs and expenditures <br />(including reimbursement for past such programs or expenditures except where this <br />Agreement restricts the use of funds solely to future Opioid Remediation) designed <br />to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid <br />use or related disorders, or (3) mitigate other alleged effects of the opioid abuse <br />crisis, including on those injured as a result of the opioid abuse crisis. Exhibit J <br />provides a non-exhaustive list of expenditures that qualify as being paid for Opioid <br />Remediation. Qualifying expenditures may include reasonable related administrative <br />expenses. <br />19. “Participating Subdivision” means a Subdivision that meets the requirements for <br />becoming a Participating Subdivision under Section VII. <br />20. “Parties” means Janssen and the State of Washington (each, a “Party”). <br />21. “Product” means any chemical substance, whether used for medicinal or non- <br />medicinal purposes, and whether natural, synthetic, or semi-synthetic, or any <br />finished pharmaceutical product made from or with such substance, that is an opioid <br />or opiate, as well as any product containing any such substance. It also includes: 1) <br />the following when used in combination with opioids or opiates: benzodiazepine, <br />carisoprodol, zolpidem, or gabapentin; and 2) a combination or “cocktail” of any <br />stimulant or other chemical substance prescribed, sold, bought, or dispensed to be <br />used together that includes opioids or opiates. For the avoidance of doubt, “Product” <br />does not include benzodiazepine, carisoprodol, zolpidem, or gabapentin when not <br />used in combination with opioids or opiates. “Product” includes but is not limited to <br />any substance consisting of or containing buprenorphine, codeine, fentanyl, <br />hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone,